tradingkey.logo
tradingkey.logo
Suchen

enVVeno Medical Corp

NVNO
Zur Watchlist hinzufügen
11.110USD
+0.310+2.80%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
7.29MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über enVVeno Medical Corp Unternehmen

enVVeno Medical Corporation is a late clinical-stage medical device company. The Company is focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The Company is developing surgical and non-surgical replacement venous valves for patients suffering from severe chronic venous insufficiency (CVI) of the deep venous system of the leg. The Company’s lead product is the VenoValve, which is a surgical replacement venous valve that is being evaluated in a U.S. pivotal study. The VenoValve is implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The Company is also developing a second product called enVVe, which is a non-surgical, transcatheter-based replacement venous valve. Both the VenoValve and enVVe are designed to act as one-way valves, to help assist in propelling blood up the veins of the leg, and back to the heart and lungs.

enVVeno Medical Corp Informationen

BörsenkürzelNVNO
Name des UnternehmensenVVeno Medical Corp
IPO-datumMay 31, 2018
CEOBerman (Robert A)
Anzahl der mitarbeiter37
WertpapierartOrdinary Share
GeschäftsjahresendeMay 31
Addresse70 Doppler
StadtIRVINE
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl92618
Telefon19492612900
Websitehttps://envveno.com/
BörsenkürzelNVNO
IPO-datumMay 31, 2018
CEOBerman (Robert A)

Führungskräfte von enVVeno Medical Corp

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.36K
-5.93%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
315.00
-1.27%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
264.00
-0.38%
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
45.00
-2.22%
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--
Dr. Hamed Alavi
Dr. Hamed Alavi
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Ms. Jennifer Bright
Ms. Jennifer Bright
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Francis Duhay
Dr. Francis Duhay
Independent Director
Independent Director
2.36K
-5.93%
Mr. Robert C. Gray
Mr. Robert C. Gray
Independent Director
Independent Director
315.00
-1.27%
Dr. Sanjay Shrivastava
Dr. Sanjay Shrivastava
Independent Director
Independent Director
264.00
-0.38%
Dr. Marc H. Glickman, M.D.
Dr. Marc H. Glickman, M.D.
Senior Vice President, Chief Medical Officer
Senior Vice President, Chief Medical Officer
45.00
-2.22%
Mr. Robert A. Berman
Mr. Robert A. Berman
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Matthew M. Jenusaitis
Mr. Matthew M. Jenusaitis
Independent Director
Independent Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von enVVeno Medical Corp?

Die fünf größten Anteilseigner von enVVeno Medical Corp sind: Dr. Francis Duhay

Wie viele Institutionen halten Anteile an enVVeno Medical Corp (NVNO)?

Mit Stand vom 2026Q1 halten 83 Institutionen Anteile an enVVeno Medical Corp, mit einem Gesamtmarktwert von etwa 184.36K, was 27.61% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -95829.00 gestiegen.